Agenus Tidigare resultatutveckling
Tidigare kriterier kontrolleras 2/6
Agenus har ökat intäkterna med en genomsnittlig årlig takt på 3.2%, medan Biotechs -branschen såg intäkterna växande på 36.2% årligen. Intäkterna har varit fallande med en genomsnittlig takt på 13.3% per år.
Viktig information
3.20%
Tillväxttakt i vinsten
16.98%
Tillväxttakt för EPS
| Biotechs Tillväxt i branschen | 17.04% |
| Intäkternas tillväxttakt | -13.28% |
| Avkastning på eget kapital | n/a |
| Nettomarginal | 51.98% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
AGEN: Phase 3 Colorectal Cancer Trial Will Support Bullish Reassessment
Analyst price targets for Agenus have been reaffirmed at $15.50, with modest adjustments to the discount rate, revenue growth assumptions, profit margin and forward P/E reflecting analysts' updated view of the stock's risk profile and earnings potential. What's in the News Agenus is advancing its botensilimab plus balstilimab (BOT+BAL) program with multiple data disclosures, including new Phase 2 results in advanced cutaneous melanoma and published Phase 1b data in treatment refractory hepatocellular carcinoma.AGEN: Phase 3 Colorectal Cancer Trial Will Drive Bullish Reassessment
Analysts now set a higher price target for Agenus, moving their fair value estimate from $12.33 to $15.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Phase 2 data from the C-800-23 study in advanced cutaneous melanoma showed a 22% confirmed objective response rate for botensilimab plus balstilimab, with median overall survival of 16.6 months and a 42% 2 year overall survival rate in the overall cohort, and no treatment related deaths reported (Key Developments).
AGEN: Late Stage Cancer Data And Access Programs Will Drive Future Upside
Analysts have reduced their price targets on Agenus by $8.00 after updating their assumptions for revenue growth, profit margins, and future P/E levels to reflect a more conservative view of the stock’s valuation inputs. What's in the News Agenus is presenting four botensilimab and balstilimab abstracts at the 2026 ASCO Annual Meeting, including first Phase 2 data in advanced cutaneous melanoma and a trial-in-progress update on the Phase 3 CO.33/BATTMAN colorectal cancer study (Key Developments).AGEN: Late Stage Gastrointestinal Cancer Data Will Drive Future Upside
Analysts have nudged their price target on Agenus higher to $8.00, reflecting updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Agenus reported Phase II data from a Memorial Sloan Kettering trial combining botensilimab, balstilimab, agenT-797, ramucirumab, and paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma, with a 77% disease control rate in 17 patients and a subset showing survival beyond 20 months (AACR Annual Meeting 2026).AGEN: Expanded Late-Stage Trials And Access Programs Will Drive Future Upside
Analysts have raised their price target on Agenus from $6.00 to $8.00. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and a higher future P/E of 28.67x compared with 19.01x previously.Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33. What's in the News Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
BOT/BAL Trials And Cost Reductions Will Shape Future Advances
Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.Agenus: Novel Drugs That Just Are Not Novel
Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Recent FDA meeting and phase 2 metastatic colorectal cancer data plummeted AGEN stock 60%, due to discouragement to file for accelerated approval. Further funding is likely to be required soon, considering high cash burn rates and the upcoming phase 3 trial in mCRC. Read the full article on Seeking AlphaThere's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
Agenus Inc. ( NASDAQ:AGEN ) shareholders are no doubt pleased to see that the share price has bounced 102% in the last...Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
Shareholders might have noticed that Agenus Inc. ( NASDAQ:AGEN ) filed its quarterly result this time last week. The...Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Agenus Inc. ( NASDAQ:AGEN ) shareholders that were waiting for something to happen have been dealt a blow with a 25...Agenus: 2024 May Finally Be The Year For A Major Turnaround
Summary Agenus is a beaten-down immuno-oncology biotech stock that has not participated in the recent biotech rally despite a promising pipeline and multiple partnerships. The company's lead asset, botensilimab (+/- balstilimab), has shown promising results in various advanced solid tumors (colorectal, pancreatic, melanoma, NSCLC, sarcomas, ovarian). A BLA is planned in mid-2024 for accelerated approval in metastatic colorectal cancer with potential for subsequent label expansion to earlier lines. Potential new partnerships are also being evaluated. Cash runway is a concern but planned transactions (sale of 2 assets and monetization of milestones/royalties from partnered programs) in 1H 2024 are expected to considerably extend cash runway. Considering AGEN's track record I am confident about these transactions. Read the full article on Seeking AlphaImproved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Agenus Inc.'s ( NASDAQ:AGEN ) price-to-sales (or "P/S") ratio of 2.9x might make it look like a strong buy right now...News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Agenus Inc. ( NASDAQ:AGEN ) shareholders will have a reason to smile today, with the analysts making substantial...Fördelning av intäkter och kostnader
Hur Agenus tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 124 | 64 | 46 | 67 |
| 31 Dec 25 | 114 | 0 | 54 | 76 |
| 30 Sep 25 | 107 | -35 | 63 | 164 |
| 30 Jun 25 | 102 | -166 | 69 | 164 |
| 31 Mar 25 | 100 | -191 | 71 | 164 |
| 31 Dec 24 | 103 | -227 | 72 | 144 |
| 30 Sep 24 | 160 | -228 | 72 | 0 |
| 30 Jun 24 | 160 | -224 | 74 | 0 |
| 31 Mar 24 | 161 | -240 | 77 | 0 |
| 31 Dec 23 | 156 | -246 | 79 | 228 |
| 30 Sep 23 | 101 | -271 | 83 | 0 |
| 30 Jun 23 | 99 | -263 | 82 | 0 |
| 31 Mar 23 | 95 | -240 | 80 | 0 |
| 31 Dec 22 | 98 | -220 | 81 | 0 |
| 30 Sep 22 | 90 | -215 | 78 | 0 |
| 30 Jun 22 | 320 | 18 | 81 | 0 |
| 31 Mar 22 | 310 | -19 | 79 | 0 |
| 31 Dec 21 | 296 | -24 | 76 | 0 |
| 30 Sep 21 | 307 | 4 | 74 | 0 |
| 30 Jun 21 | 69 | -226 | 67 | 0 |
| 31 Mar 21 | 85 | -190 | 65 | 0 |
| 31 Dec 20 | 88 | -181 | 59 | 0 |
| 30 Sep 20 | 91 | -174 | 52 | 0 |
| 30 Jun 20 | 97 | -168 | 49 | 0 |
| 31 Mar 20 | 85 | -171 | 46 | 0 |
| 31 Dec 19 | 150 | -108 | 46 | 0 |
| 30 Sep 19 | 122 | -126 | 43 | 0 |
| 30 Jun 19 | 115 | -113 | 41 | 0 |
| 31 Mar 19 | 115 | -87 | 39 | 0 |
| 31 Dec 18 | 37 | -160 | 37 | 0 |
| 30 Sep 18 | 39 | -147 | 37 | 0 |
| 30 Jun 18 | 29 | -151 | 36 | 0 |
| 31 Mar 18 | 18 | -158 | 35 | 0 |
| 31 Dec 17 | 43 | -121 | 34 | 0 |
| 30 Sep 17 | 40 | -112 | 33 | 0 |
| 30 Jun 17 | 41 | -116 | 33 | 0 |
| 31 Mar 17 | 44 | -113 | 32 | 0 |
| 31 Dec 16 | 23 | -127 | 33 | 0 |
| 30 Sep 16 | 25 | -117 | 33 | 0 |
| 30 Jun 16 | 27 | -89 | 31 | 0 |
| 31 Mar 16 | 27 | -101 | 32 | 0 |
| 31 Dec 15 | 25 | -88 | 28 | 0 |
| 30 Sep 15 | 19 | -98 | 25 | 0 |
| 30 Jun 15 | 14 | -93 | 23 | 0 |
Kvalitetsintäkter: AGEN har en stor engång vinst av $110.3M {1 månader till 31st March, 2026 1 månader) 31st March, 2026.
Växande vinstmarginal: AGEN blev lönsam tidigare.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: AGEN har blivit lönsamt under de senaste 5 åren och ökat intäkterna med 3.2% per år.
Accelererande tillväxt: AGEN har blivit lönsamt under det senaste året, vilket gör det svårt att jämföra vinsttillväxttakten med 5-årsgenomsnittet.
Resultat vs industri: AGEN har blivit lönsamt under det senaste året, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Biotechs branschen ( 54.5% ).
Avkastning på eget kapital
Hög ROE: AGEN s skulder överstiger dess tillgångar, så det är svårt att beräkna dess avkastning på eget kapital.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/11 03:16 |
| Aktiekurs vid dagens slut | 2026/06/11 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Agenus Inc. bevakas av 7 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |